Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus ipilimumab (IPI): CheckMate 142

被引：0

作者：

Andre, T. ^{[1
]}

Overman, M. ^{[2
]}

Lonardi, S. ^{[3
]}

Aglietta, M. ^{[4
,5
]}

McDermott, R. ^{[6
]}

Wong, K. Y. M. ^{[7
]}

Morse, M. ^{[8
]}

Hendlisz, A. ^{[9
]}

Moss, R. A. ^{[10
]}

Ledeine, J-M. ^{[11
]}

Tang, H. ^{[12
]}

Cao, Z. A. ^{[10
]}

Kopetz, S. ^{[13
]}

机构：

[1] Hop St Antoine, Med Oncol, Paris, France

[2] MD Anderson Canc Ctr, Gastrointestinal Med Oncol, Houston, TX USA

[3] Ist Oncol Veneto IRCCS, Med Oncol, Padua, Italy

[4] Inst Canc Res & Treatment, Div Med Oncol, Dept Oncol Sci, Candiolo, Italy

[5] Univ Torino, Med Sch, Turin, Italy

[6] St Vincents Univ Hosp, Med Oncol, Dublin, Ireland

[7] Univ Sydney, Sydney Med Sch, Med Oncol, Sydney, NSW, Australia

[8] Duke Univ, Off Res Adm, Dept Surg, Durham, NC USA

[9] Inst Jules Bordet, Oncol, Gastroenterol, Brussels, Belgium

[10] Bristol Myers Squibb, Res & Dev, Princeton, NJ USA

[11] Bristol Myers Squibb, Res & Dev, Braine Lalleud, Belgium

[12] Bristol Myers Squibb, Res & Dev, Princeton, NJ USA

[13] MD Anderson Canc Ctr, GI Med Oncol, Houston, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

484PD

引用

页数：1